A new Ipas report published in the International Journal of Gynecology and Obstetrics assesses the global availability of misoprostol for gynecological indications, citing increased sales of misoprostol in sub-Saharan Africa and Asia where Venture Strategies works to register and increase access to the life-saving drug. Full article here.